Long‑term GLP‑1 safety flags
A 5‑year analysis of 146,000 adults linked GLP‑1 use to a 30% higher osteoporosis risk, a 100% higher osteomalacia risk, and a 12% higher gout risk — raising important long‑term safety questions for chronic prescribing. These are observational signals that should prompt monitoring, not automatic causation claims. x.com/DrCHuber/status/2032422637151097196
The analysis was presented at the American Academy of Orthopaedic Surgeons annual meeting in New Orleans (March 2–6, 2026) by Michigan State investigators led by Muaaz Wajahath. aaos-annualmeeting-presskit.org Researchers used a large federated national electronic medical‑record database and propensity‑score matched GLP‑1 users 1:1 to nonusers, with 73,483 patients in each arm (≈146,966 total). firstwordpharma.com The GLP‑1 agents evaluated explicitly included semaglutide, liraglutide, dulaglutide and exenatide in the treated group. drugs.com Authors reported absolute five‑year incidences — osteoporosis 4.1% vs 3.2% (risk ratio 1.29), gout 7.4% vs 6.6% (risk ratio 1.12), and osteomalacia 0.2% vs 0.1% (risk ratio 2.55) — and noted statistical significance for those differences. drugs.com The work is a retrospective, claims/EMR‑based analysis that has been presented but not yet published in a peer‑reviewed journal, and the authors acknowledge residual confounding and limitations inherent to observational matching. iheart.com At the same AAOS meeting the press materials also highlighted parallel investigations into GLP‑1s and short‑term orthopaedic outcomes, underlining that these safety signals are part of a broader research push rather than a single definitive finding. aaos-annualmeeting-presskit.org
